GSK completes divestment of thrombosis brands and related manufacturing site to Aspen
GlaxoSmithKline (“GSK”) today completed the previously announced divestment of its thrombosis brands, ArixtraTM and FraxiparineTM to the Aspen Group (Aspen) for £700 million.
Source: GSK news - Category: Pharmaceuticals Source Type: news
More News: Pharmaceuticals | Thrombosis